logo
Plus   Neg
Share
Email

Merck: KEYTRUDA Approved For New Indication In China - Quick Facts

Merck (MRK) said KEYTRUDA, the company's anti-PD-1 therapy, has been approved by the National Medical Products Administration in China as monotherapy for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 as determined by a fully validated test, following failure of one prior line of systemic therapy. The company noted that, with the new approval, KEYTRUDA is now approved for five indications across three different types of cancer in China.

Separately, Merck reported results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company's investigational 15-valent pneumococcal conjugate vaccine. The company said V114 met safety and immunogenicity objectives in initial phase 3 studies in adults. The company plans to continue to work with the FDA and other regulatory authorities around the world on filing plans for licensure of this vaccine as more data from the Phase 3 program become available.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT